Valproate-induced hyperammonemic encephalopathy is an unusual but serious adverse effect that is usually characterized by the acute. onset of impaired consciousness, focal neurological symptoms and increased seizure frequency. It has been reported to occur at therapeutic valproate levels. We report a patient who developed valproate-induced hyperammonemic encephalopathy after a short treatment with valproate and was successfully treated with levocamitine. We discuss this patient and review the literature regarding the use of levocarnitine in similar patients.
Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine / A. Rigamonti, G. LAURIA PINTER, G. Grimod, G. Bianchi, A. Salmaggi. - In: JOURNAL OF CLINICAL NEUROSCIENCE. - ISSN 0967-5868. - 21:4(2014 Apr), pp. 690-691.
Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine
G. LAURIA PINTER;
2014
Abstract
Valproate-induced hyperammonemic encephalopathy is an unusual but serious adverse effect that is usually characterized by the acute. onset of impaired consciousness, focal neurological symptoms and increased seizure frequency. It has been reported to occur at therapeutic valproate levels. We report a patient who developed valproate-induced hyperammonemic encephalopathy after a short treatment with valproate and was successfully treated with levocamitine. We discuss this patient and review the literature regarding the use of levocarnitine in similar patients.File | Dimensione | Formato | |
---|---|---|---|
VHE_JClinNeurosci2014.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
90.93 kB
Formato
Adobe PDF
|
90.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.